 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
29 News |  |
- ||| olopatadine / Generic mfg.
Trial completion: Azelastine Allergen Chamber - Onset of Action Study (clinicaltrials.gov) - Mar 21, 2024
P2, N=84, Completed, Sponsor: MEDA Pharma GmbH & Co. KG
Active, not recruiting --> Completed
- || olopatadine / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Azelastine Allergen Chamber - Onset of Action Study (clinicaltrials.gov) - Jan 31, 2024
P2, N=84, Active, not recruiting, Sponsor: MEDA Pharma GmbH & Co. KG
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| olopatadine / Generic mfg.
New P2 trial: Azelastine Allergen Chamber - Onset of Action Study (clinicaltrials.gov) - Nov 13, 2023
P2, N=84, Recruiting, Sponsor: MEDA Pharma GmbH & Co. KG
- ||| olopatadine / Generic mfg., Ryaltris (olopatadine/mometasone) / Glenmark
New AusPAR for Ryaltris (olopatadine and mometasone furoate) for allergic rhinitis and rhinoconjunctivitis. Read more: https://t.co/jWd6OszTk7 (Twitter) - Mar 22, 2023
- | olopatadine / Generic mfg.
Journal, Real-world evidence, Real-world: Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study. (Pubmed Central) - Jan 24, 2023
Current findings showed that participants using OLO/MOM were more satisfied with their overall treatment compared to participants using AZE/FLU, particularly with sensory attributes, thus highlighting the suitability of OLO/MOM for people with AR who value sensory attributes. Prescribers of AR treatments are encouraged to discuss treatment attributes with patients to facilitate shared decision-making.
- | Ryaltris (olopatadine/mometasone) / Glenmark
Journal: Olopatadine/mometasone (Ryaltris) for allergic rhinitis. (Pubmed Central) - Jan 19, 2023
Prescribers of AR treatments are encouraged to discuss treatment attributes with patients to facilitate shared decision-making. No abstract available
- | Ryaltris (olopatadine/mometasone) / Glenmark
Journal: Efficacy and safety of GSP301 nasal spray in children aged 6-11 with seasonal allergic rhinitis. (Pubmed Central) - Nov 9, 2022
P3
No abstract available GSP301 was well tolerated and efficacious for treating SAR symptoms in pediatric patients and showed a favorable safety profile.
- || Ryaltris (olopatadine/mometasone) / Glenmark
Review, Journal: Intranasal Olopatadi: Mometasone in the Treatment of Seasonal Allergic Rhinitis. (Pubmed Central) - Sep 22, 2022
Due to its quick and sustained onset of action, OM may be an ideal agent for initial treatment of moderate-severe SAR for patients 12 years and older. OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR.
- | Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment change, Trial withdrawal, Trial primary completion date: Impact of RYALTRIS (clinicaltrials.gov) - Apr 6, 2022
P=N/A, N=0, Withdrawn, Sponsor: Community and Patient Preference Research Pty Ltd
OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR. N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Mar 2022
- || Ryaltris (olopatadine/mometasone) / Glenmark
Retrospective data, Review, Journal: Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. (Pubmed Central) - Mar 23, 2022
GSP301 is a safe and well-tolerated medication. It showed short-term benefits for seasonal and perennial AR, but may not help to improve patients' quality of life and rhinitis control in the long run.
- | Ryaltris (olopatadine/mometasone) / Glenmark
New trial: Impact of RYALTRIS (clinicaltrials.gov) - Nov 21, 2021
P=N/A, N=100, Recruiting, Sponsor: Community and Patient Preference Research Pty Ltd
- olopatadine / Generic mfg.
[VIRTUAL] Clinically Meaningful Improvement in Total Rhinoconjunctivitis Score with Olopatadine/mometasone Combination Nasal Spray in Patients with Seasonal Allergic Rhinitis: A Pooled Analysis () - Jul 29, 2021 - Abstract #ERS2021ERS_1859;
Time to response was significantly faster with GSP301 (30% percentile 4 days) than placebo (10 day, p<0.001), OLO (7 days, p=0.035) and MF (7 days, p=0.017). GSP301 provides a clinically meaningful and statistically significant improvement in total nasal and ocular symptoms compared to individual monotherapies.
- Ryaltris (olopatadine/mometasone) / Glenmark
Clinically meaningful effect on nasal symptoms and quality of life improvements with olopatadine/mometasone combination nasal spray in patients with seasonal allergic rhinitis: A pooled analysis () - Apr 20, 2021 - Abstract #EAACI2021EAACI_903;
P2, P3
Treatment-emergent adverse events were low and comparable across treatments (reported elsewhere) . Conclusion This shows that GSP301 provides a clinical meaningful response in nasal symptoms in patients with SAR as well as improves QoL.
- || Ryaltris (olopatadine/mometasone) / Glenmark
Clinical, Journal: Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. (Pubmed Central) - Jul 16, 2020
P3
Conclusion This shows that GSP301 provides a clinical meaningful response in nasal symptoms in patients with SAR as well as improves QoL. Twice-daily GSP301 was well tolerated and provided statistically significant and clinically meaningfulimprovements in PAR nasal symptoms versus placebo over 52 weeks and demonstrated a favorable safety profile and efficacy.
- || Ryaltris (olopatadine/mometasone) / Glenmark
Clinical, Journal: Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. (Pubmed Central) - Jun 29, 2020
P3
Twice-daily GSP301 was well tolerated and provided statistically significant and clinically meaningfulimprovements in PAR nasal symptoms versus placebo over 52 weeks and demonstrated a favorable safety profile and efficacy. GSP301 was efficacious and well tolerated for the treatment of SAR symptoms compared with placebo, witha rapid onset of action of 15 minutes in patients greater than or equal to 12 years of age.
- || Ryaltris (olopatadine/mometasone) / Glenmark
Clinical, Journal: Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis. (Pubmed Central) - Apr 28, 2020
P2
GSP301 was efficacious and well tolerated for the treatment of SAR symptoms compared with placebo, witha rapid onset of action of 15 minutes in patients greater than or equal to 12 years of age. Twice-daily GSP301 treatment was efficacious and well tolerated, providing statistically significant and clinically meaningful improvements in rTNSS (primary endpoint) versus placebo and both monotherapies.
- || Ryaltris (olopatadine/mometasone) / Glenmark
Clinical, Journal: Efficacy and safety of olopatadine/mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. (Pubmed Central) - Jan 8, 2020
P3
GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). No abstract available
- | Astelin (azelastine) / Mylan, Ryaltris (olopatadine/mometasone) / Glenmark
Journal: Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in an Environmental Exposure Chamber Study. (Pubmed Central) - Nov 24, 2019
P2
No abstract available In an EEC model, GSP301 BID and QD treatments were well tolerated and provided statistically significant and clinically meaningful SAR symptom improvement versus placebo.
- ||||||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial completion: GSP 301-305: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Jan 18, 2019
P3, N=446, Completed, Sponsor: Glenmark Specialty S.A.
In an EEC model, GSP301 BID and QD treatments were well tolerated and provided statistically significant and clinically meaningful SAR symptom improvement versus placebo. Recruiting --> Completed
- |||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment open: GSP 301-305: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Apr 6, 2018
P3, N=450, Recruiting, Sponsor: Glenmark Specialty S.A.
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Ryaltris (olopatadine/mometasone) / Glenmark
New P3 trial: GSP 301-305: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Mar 12, 2018
P3, N=450, Not yet recruiting, Sponsor: Glenmark Specialty S.A.
- ||||| Ryaltris (olopatadine/mometasone) / Glenmark
New P2 trial: Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Feb 23, 2018
P2, N=180, Completed, Sponsor: Glenmark Pharmaceuticals Ltd. India
- ||||||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial completion: GSP 301-303: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Sep 19, 2017
P3, N=600, Completed, Sponsor: Glenmark Specialty S.A.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial completion, Monotherapy: GSP 301-304: Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Mar 13, 2017
P3, N=1176, Completed, Sponsor: Glenmark Specialty S.A.
Active, not recruiting --> Completed Recruiting --> Completed
- |||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment open, Monotherapy: GSP 301-304: Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Sep 15, 2016
P3, N=1176, Recruiting, Sponsor: Glenmark Specialty S.A.
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Ryaltris (olopatadine/mometasone) / Glenmark
New P3 trial, Monotherapy: GSP 301-304: Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Aug 16, 2016
P3, N=1176, Not yet recruiting, Sponsor: Glenmark Specialty S.A.
- ||||||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial completion, Monotherapy: GSP 301-301: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Aug 9, 2016
P3, N=1176, Completed, Sponsor: Glenmark Specialty S.A.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment closed: GSP 301-303: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Jul 7, 2016
P3, N=600, Active, not recruiting, Sponsor: Glenmark Specialty S.A.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment closed, Monotherapy: GSP 301-301: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Jul 7, 2016
P3, N=1176, Active, not recruiting, Sponsor: Glenmark Specialty S.A.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment open: GSP 301-303: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Apr 14, 2016
P3, N=600, Recruiting, Sponsor: Glenmark Specialty S.A.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment open, Monotherapy: GSP 301-301: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Apr 14, 2016
P3, N=1176, Recruiting, Sponsor: Glenmark Specialty S.A.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Ryaltris (olopatadine/mometasone) / Glenmark
New P3 trial: GSP 301-303: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR) (clinicaltrials.gov) - Mar 16, 2016
P3, N=600, Not yet recruiting, Sponsor: Glenmark Specialty S.A.
- ||||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial initiation date, Trial primary completion date, Monotherapy: GSP 301-301: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Jan 15, 2016
P3, N=1104, Not yet recruiting, Sponsor: Glenmark Specialty S.A.
Not yet recruiting --> Recruiting Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Mar 2016 --> Jul 2016
- || Ryaltris (olopatadine/mometasone) / Glenmark
New P3 trial, Monotherapy: GSP 301-301: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR) (clinicaltrials.gov) - Dec 16, 2015
P3, N=1104, Not yet recruiting, Sponsor: Glenmark Specialty S.A.
- |||| Ryaltris (olopatadine/mometasone) / Glenmark
Trial completion, Monotherapy: To Study GSP 301 in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - May 19, 2015
P2, N=1106, Completed, Sponsor: Glenmark Pharmaceuticals Ltd. India
Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Completed
- |||| Ryaltris (olopatadine/mometasone) / Glenmark
Enrollment open, Monotherapy: To Study GSP 301 in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - Jan 16, 2015
P2, N=1106, Recruiting, Sponsor: Glenmark Pharmaceuticals Ltd. India
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Ryaltris (olopatadine/mometasone) / Glenmark
New P2 trial, Monotherapy: To Study GSP 301 in Patients With Seasonal Allergic Rhinitis (clinicaltrials.gov) - Dec 19, 2014
P2, N=1106, Not yet recruiting, Sponsor: Glenmark Pharmaceuticals Ltd. India